Epic won FDA clearance for its deterioration score with rival AgileMD's algorithm as the benchmark
The FDA found Epic's rebuilt patient-deterioration score substantially equivalent to AgileMD's eCARTv5, making the challenger's algorithm the benchmark the EHR giant had to match. With a mortality study behind it, Epic's bundled score resets the math for hospital AI vendors.
Vincent Jiang · 3 min read
In September the FDA cleared Deterioration Index Version 2, Epic's rebuilt early-warning score that flags hospitalized adults likely to need escalated care within 24 hours or to die within 72, through the 510(k) medical-device pathway 1. To win that clearance, Epic had to prove the software substantially equivalent to eCARTv5, a competing score from AgileMD, a San Francisco company founded at the University of Chicago by physician Dana Edelson and CEO Borna Safabakhsh 1. The regulator made the challenger's algorithm the yardstick the industry giant had to match 1.
The challenger drew first blood, so Epic rebuilt
The history explains the clearance. A 2024 study across seven Yale New Haven hospitals ranked Epic's earlier index near the bottom of six early-warning scores, and noted the tool had never been formally vetted by the FDA 1. AgileMD's eCART, cleared by the FDA in June 2024, was the winner of that comparison 2.
Yale New Haven adopted eCART, and by August 2025 reported a 13% relative reduction in overall mortality, 1.2% in absolute terms 3. Epic submitted its V2 application on January 2, 2026, tested it on about 10.7 million score observations from three U.S. sites, and posted an area under the curve of 0.83 for the combined outcome and 0.94 for mortality alone 1.
The receipts: 18% fewer deaths, no ICU surge
The outcome evidence came from RWJBarnabas Health and Rutgers Robert Wood Johnson Medical School, published in NEJM AI in July 2026 4. Across 23,132 patients in 11 hospitals, in-hospital mortality among high-risk patients fell from 23.1% to 18.6%, an 18% reduction in risk-adjusted odds of death 4. Rapid-response evaluations rose from 25.3% to 37.5% without a surge in ICU transfers, because red-alert scores pushed notifications straight to rapid-response teams' phones instead of sitting on a desktop dashboard 4.
At RWJBarnabas, deaths fell and rapid-response checks rose after automated alerts
- Before rollout
- After rollout
Data
| Before rollout | After rollout | Change | |
|---|---|---|---|
| High-risk mortality | 23.1% | 18.6% | -19.5% |
| Rapid-response evaluations | 25.3% | 37.5% | +48.2% |
The wrinkle: at the medium-risk threshold, V2's sensitivity was 26% for Black patients and 32% for Hispanic patients against 51% for white patients, though a site-by-site analysis narrowed the Black-white gap 1. Every hospital still sets its own alert thresholds 1.
At medium risk, the rebuilt score flagged half as many Black patients as white
Data
| Sensitivity at medium-risk threshold | |
|---|---|
| Black patients | 26% |
| Hispanic patients | 32% |
| White patients | 51% |
Distribution versus accuracy
The money math now runs through procurement. Epic's score ships inside the EHR hospitals already license, and a Redesign Health survey of 112 executives at Epic-based health systems found 71% describe their organizations as Epic-first, not one prefers external vendors by default, and 49% demand significantly higher ROI from outside vendors before they buy 5.
AgileMD's remaining edge is accuracy plus reach: 400-plus hospitals, 4.4 million-plus patient encounters and 4,800-plus clinical pathways the score feeds 2. Neither company is listed, so the pressure lands on standalone early-warning vendors' pricing and on hospital AI budgets rather than on any ticker 25.
The renewal question decides which advantage wins
Yale New Haven is the tell: the system that panned Epic's first score and adopted the rival's. Whether it renews with eCART or drifts back to the bundled tool decides which advantage, accuracy or distribution, actually wins 13. Watch too that AgileMD's newsroom has posted nothing since February 2, 2026, while Epic's clearance is a month old 3. A clearance after years of unregulated use is not the finish line; it is the starting gun.
Get Health by email, free
AI in medicine, pharma and biotech. In our daily email, every weekday.
